Top

European Journal of Medical Research

Published in:

Open Access 01-12-2016 | Research

Serum prolactin as a biomarker for the study of intracerebral dopamine effect in adult patients with phenylketonuria: a cross-sectional monocentric study

Authors: Eszter Juhász, Erika Kiss, Erika Simonova, Attila Patócs, Peter Reismann

Published in: European Journal of Medical Research | Issue 1/2016

Abstract

Background

It has been previously postulated that high phenylalanine (Phe) might disturb intracerebral dopamine production, which is the main regulator of prolactin secretion in the pituitary gland. Previously, various associations between Phe and hyperprolactinemia were revealed in studies performed in phenylketonuria (PKU) children and adolescents. The aim of the present study was to clarify whether any relation between serum phenylalanine and prolactin levels can be found in adult PKU patients.

Patients and methods

We conducted a cross-sectional, monocentric study including 158 adult patients (male n = 68, female n = 90) with PKU. All patients were diagnosed during newborn screening and were treated since birth. Serum Phe, tyrosine (Tyr), prolactin (PRL), and thyroid-stimulating hormone (TSH) levels were measured, and Phe/Tyr ratio was calculated. Males and females were analyzed separately because the serum prolactin level is gender-dependent.

Results

No significant correlations were found between serum phenylalanine, tyrosine, or the Phe/Tyr ratio and serum prolactin level either in the male or in the female group.

Conclusions

In treated adult PKU patients, the serum prolactin level may not be significantly influenced by Phe or Tyr serum levels.

Blau N, Erlandsen H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab. 2004;82:101–11.CrossRefPubMed

Güttler F, Lou H. Dietary problems of phenylketonuria: effect on CNS transmitter and their possible role in behaviour and neurophysiological function. J Inherit Metab Dis. 1986;9(Suppl. 2):169–77.CrossRefPubMed

Velema M, Boot E, Engelen M, Hollak C. Parkinsonism in phenylketonuria: a consequence of dopamine depletion? JIMD Report. 2015;20:35–8.CrossRef

McKean CM. The effect of high phenylalanine concentration on serotonin and catecholamine metabolism in the human brain. Brain Res. 1972;47:469–76.CrossRefPubMed

Curtius HC, Niederwieser A, Viscontini M, Leimbacher W, Wegmann H, Blehova B, Rey F, Schaub J, Schmidt H. Serotonin and dopamine synthesis in phenylketonuria. Adv Exp Med Biol. 1981;133:277–91.CrossRefPubMed

Denecke J, Schlegel W, Koch HG, Feldmann R, Harms E, Weglage J. Prolactin, a marker for cerebral dopamine deficiency in patients suffering from phenylketonuria (PKU)? J Inherit Metab Dis. 2000;23:849–51.CrossRefPubMed

van Vliet D, Bruinenberg VM, Mazzola PN, van Faassen MHJR, de Blaauw P, Kema IP, Heiner-Fokkema MR, van Anholt RD, van der Zee EA, van Spronsen FJ. Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms: proof of principle in phenylketonuria mice. PLoS One. 2015;10(12):e0143833.CrossRefPubMedPubMedCentral

de Groot MJ, Hoeksma M, Reijngoud DJ, de Valk HW, Paans AM, Suaer PJ, van Spronsen FJ. Phenylketonuria: reduced tyrosine brain influx relates to reduced cerebral protein synthesis. Orphanet J Rare Dis. 2013;8:133.CrossRefPubMedPubMedCentral

Burlina AB, Bonafe L, Ferrari V, Suppiej A, Zacchello F, Burlina AP. Measurement of neurotransmitter metabolites in the cerebrospinal fluid of phenylketonuric patients under dietary treatment. J Inherit Metab Dis. 2000;23:313–6.CrossRefPubMed

10.

Ben-Jonathan N, Hnasko R. Dopamine as a Prolactin (PRL) inhibitor. Endocr Rev. 2001;22:724–63.CrossRefPubMed

11.

Spada M, Ferraris S, Ferrero GB, Sartore M, Lanza C, PErfetto F, de Sanctis L, Dompe C, Blau N, Ponzone A. Monitoring treatment in tetrahydrobiopterin deficiency by serum prolactin. J Inherit Metab Dis. 1996;19:231–3.CrossRefPubMed

12.

van Vliet D, Anjema K, Jahja R, de Groot MJ, Liemburg GB, Heiner-Fokkema MR, van der Zee EA, Derks TGJ, Kema IP, van Spronsen FJ. BH4 treatment in BH4-responsive PKU patients: preliminary data on blood prolactin concentrations suggest increased cerebral dopamin concentrations. Mol Genet Metab. 2015;114:29–33.CrossRefPubMed

13.

Carlson HE, Hyman DB, Blitzer MG. Evidence for an intracerebral action of phenylalanine in stimulation of prolactin secretion: interaction of large neutral amino acids. J Clin Endocrinol Metab. 1990;70:814–6.CrossRefPubMed

14.

Carlson HE, Hyman DB, Bauman C, Koch R. Prolactin responses to phenylalanine and tyrosin in phenylketonuria. Metabolism. 1992;41:518–21.CrossRefPubMed

15.

Krause W, Halminski M, McDonald L, Dembure P, Salvo R, Freides D, Elsas L. Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. J Clin Invest. 1985;75:40–8.CrossRefPubMedPubMedCentral

16.

Schulpis KH, Papakonstantinou E, Michelakakis H, Theodoridis Th, Papandreou UR, Constantopoulos A. Elevated serum prolactin concentration in phenylketonuric patients on a ‘loose diet’. Clin Endocrinol. 1998;48:99–101.CrossRef

17.

van Spronsen FJ, van Dijk T, Smit GP, van Rijn M, Reijngoud DJ, Berger R, Heymans HS. Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria. Am J Clin Nutr. 1996;64:916–21.PubMed

18.

Landvogt C, Mengel E, Bartenstein P, Buchholz HG, Schreckenberger M, Siessmeier T, Scheurich A, Feldmann R, Weglage J, Cumming P, Zepp F, Ullrich K. Reduced cerebral fluoro-l-dopamine uptake in adult patients suffering from phenylketonuria. J Cereb Blood Flow Metab. 2008;28(4):824–31.CrossRefPubMed

19.

Wang KD, Zhou ZS, Shen M, Hong W, Yu WM. Quantification of phenylalanine in the brain of patients with hyperphenylalaninemia by (1)H magnetic resonance spectroscopy. Zhonghou Er Ke Za Zhi. 2009;47(2):119–23.

20.

Weglage J, Wiedermann D, Denecke J, Feldmann R, Koch HG, Ullrich K, Möller HE. Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria. J Inherit Metab Dis. 2002;25(6):431–6.CrossRefPubMed

Title: Serum prolactin as a biomarker for the study of intracerebral dopamine effect in adult patients with phenylketonuria: a cross-sectional monocentric study
Authors: Eszter Juhász
Erika Kiss
Erika Simonova
Attila Patócs
Peter Reismann
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2016
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-016-0212-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Serum prolactin as a biomarker for the study of intracerebral dopamine effect in adult patients with phenylketonuria: a cross-sectional monocentric study

Abstract

Background

Patients and methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Hepatitis B and human immunodeficiency virus co-infection among pregnant women in resource-limited high endemic setting, Addis Ababa, Ethiopia: implications for prevention and control measures

Waiting time for radiation therapy after breast-conserving surgery in early breast cancer: a retrospective analysis of local relapse and distant metastases in 615 patients

Total hip arthroplasty-related osteogenic osteosarcoma: case report and review of the literature

Longitudinal strain bull’s eye plot patterns in patients with cardiomyopathy and concentric left ventricular hypertrophy

How rapid is rapid? Exemplary results of real-life rapid rule-out troponin timing in troponin-positive acute coronary syndromes without persistent ST-segment elevation in two contrasting German chest pain unit facilities

Association of CYP1A1, GSTM1 and GSTT1 gene polymorphisms with risk of non-small cell lung cancer in Andhra Pradesh region of South India